Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 4:01 AM
Ignite Modification Date:
2025-12-26 @ 2:54 AM
NCT ID:
NCT00996502
Group ID:
EG000
Title:
Combination Regimen
Description:
Bevacizumab, Erlotinib, Docetaxel, Prednisone (dose escalation)
Phase I:
* Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid
* Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid
* Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid
Docetaxel: Phase I:
* Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle
* Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle
* Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle
Bevacizumab: 15mg/kg of Bevacizumab every 3 weeks
Erlotinib: 200 mg of Erlotinib PO daily days 2-16
Prednisone: 5 mg of Prednisone PO bid
Deaths Number Affected:
0
Deaths Number At Risk:
None
Serious Number Affected:
0
Serious Number At Risk:
0
Other Number Affected:
0
Other Number At Risk:
0
Study:
NCT00996502
Results Section:
NCT00996502
Adverse Events Module:
NCT00996502